Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers by Sakai, Wataru et al.
Sakai, et al.  1 
Title:  
Secondary mutations as a mechanism of cisplatin resistance in 
BRCA2-mutated cancers 
 
Authors: Wataru Sakai
1, 2
, Elizabeth M. Swisher
3, 6
, Beth Y. Karlan
4
, Mukesh K. 
Agarwal
5
, Jake Higgins
6, 7
, Cynthia Friedman
1
, Emily Villegas
1, 2
, Céline Jacquemont
1, 2
, 
Daniel J. Farrugia
5
, Fergus J. Couch
5
, Nicole Urban
2
, Toshiyasu Taniguchi
1, 2 
 
1 
Division of Human Biology  
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA 
2
 Division of Public Health Sciences 
Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA 
3
 Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 
98195-7720, USA. 
4
 Cedars-Sinai Medical Center, Department of Obstetrics and Gynecology, Los Angeles, 
CA 90048-1865, USA 
5
 Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 
Rochester, MN 55905, USA. 
6
 Department of Medicine, University of Washington, Seattle, WA 98195-7720, USA 
7
 Department of Genome Sciences, University of Washington, Seattle, WA 98195-7720, 
USA. 
 
Corresponding author: Toshiyasu Taniguchi 
Divisions of Human Biology and Public Health Sciences 
Fred Hutchinson Cancer Research Center 
1100 Fairview Ave. N., C1-015 
Seattle, WA 98109-1024, USA 
Phone: 206-667-7283 
Fax: (206) 667-5815 
email: ttaniguc@fhcrc.org
Sakai, et al.  2 
 
 Ovarian carcinomas with mutations in the tumor suppressor BRCA2 are 
particularly sensitive to platinum compounds 
1
. However, such carcinomas 
ultimately develop cisplatin resistance. The mechanism of that resistance is largely 
unknown 
2
. Here we show that acquired resistance to cisplatin can be mediated by 
secondary intragenic mutations in BRCA2 that restore the wild-type BRCA2 reading 
frame. First, in a cisplatin-resistant BRCA2-mutated breast cancer cell line, 
HCC1428, a secondary genetic change in BRCA2 rescued BRCA2 function. Second, 
cisplatin selection of a BRCA2-mutated pancreatic cancer cell line, Capan-1 
3,4
, led 
to 5 different secondary mutations that restored the wild-type BRCA2 reading 
frame. All clones with secondary mutations were resistant both to cisplatin and to a 
poly(ADP-ribose) polymerase (PARP) inhibitor (AG14361). Finally, we evaluated 
recurrent cancers from patients whose primary BRCA2-mutated ovarian 
carcinomas were treated with cisplatin. The recurrent tumor that acquired cisplatin 
resistance had undergone reversion of its BRCA2 mutation. Our results suggest that 
secondary mutations that restore the wild-type BRCA2 reading frame may be a 
major clinical mediator of acquired resistance to platinum-based chemotherapy. 
 Women with ovarian cancer generally have a high initial response to 
platinum-based chemotherapy, but over time the majority of ovarian carcinomas become 
refractory, and most patients die with progressive chemoresistant disease 
2
. The 
molecular basis of initial platinum sensitivity and acquired resistance remains largely 
unknown. Individuals with germline mutations in BRCA1 or BRCA2 (BRCA1/2) have an 
increased risk of developing cancer in the breast and ovary 
5
 as well as in some other 
organs including the pancreas and prostate 
6
. BRCA2 is identical to the Fanconi anemia 
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(FA) gene FANCD1 
7
. The BRCA2 protein directly binds to and regulates RAD51, an 
essential protein for DNA repair through homologous recombination (HR) 
8
. Tumors 
from BRCA1/2 mutation carriers usually have deletion of the wild-type allele at the 
BRCA1/2 locus and are BRCA1/2-deficient 
9-11
. BRCA1/2-deficient cancer cells are 
hypersensitive to DNA-crosslinking agents including cisplatin 
1, 12 
. Therefore, cisplatin 
or its derivative, carboplatin, is a logical choice for the treatment of BRCA1/2-mutated 
tumors 
13
 and women with BRCA1/2-mutated ovarian carcinoma have a better prognosis 
than those without BRCA1/2 mutation if they receive platinum-based therapy 
14, 15
. 
However, even BRCA1/2-mutated tumors eventually develop platinum resistance. 
In several genetic disorders such as FA, spontaneous genetic alterations compensating for 
inherited disease-causing mutations have been described 
16
. These alterations in FA 
include secondary genetic changes of one of the mutated FA alleles, such as 
back-mutations to wild-type, compensatory mutations in cis, intragenic crossovers, and 
gene conversion 
16-18
. We speculated that secondary mutations in BRCA2-mutated alleles 
might also occur in cancer cells during chemotherapy. 
 To study the mechanism of acquired cisplatin resistance of BRCA2-mutated 
cancer, first we screened 12 human breast cancer cell lines for alterations in BRCA2 
protein expression (Fig. 1a). A pancreatic cancer cell line, Capan-1 
3, 4
, with a truncated 
BRCA2 protein, was used as a control.  
 From breast cancer cell line, HCC1428 
19
, BRCA2 protein was undetectable by 
western blotting using anti-BRCA2 (Ab-1), which recognizes the middle part of BRCA2 
(Fig. 1a) but was detectable with anti-BRCA2 (Ab-2) that recognizes the BRCA2 
C-terminus. The small size of HCC1428 BRCA2 identified by Ab-2 suggested that the 
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protein might have an internal in-frame deletion. Constitutional DNA from a lymphoblast 
cell line (HCC1428BL) from the same patient had one wild-type BRCA2 allele and one 
mutant allele with a frameshift mutation, 6174delT, which is common in the Ashkenazi 
Jewish population (Figs. 1b and S1) 
20
.  
 Sequence of genomic DNA from HCC1428 cancer cells revealed no wild-type 
allele and a mutant allele with a 2135-basepair deletion surrounding the original 
6174delT mutation and the exon 11/intron 11 junction (Figs. 1c and S1). Sequence of 
cDNA indicated that this deletion activated two cryptic splice donor sites in exon 11, 
resulting in expression of two transcripts with in-frame deletions (Figs. 1d, and S1). 
HCC1428 transcript 1 had a 2640-basepair deletion and encoded a protein lacking amino 
acids 1401 to 2281. Transcript 2 had a 2187-basepair deletion and encoded a protein 
lacking amino acids 1552 to 2281 (Figs. 1d, 1e and S1). Both HCC1428 BRCA2 proteins 
retain the single-strand DNA (ssDNA) binding domain and the C-terminus nuclear 
localization signals (NLS), whereas these domains are lost in BRCA2.6174delT (Fig. 1e). 
A recent report that only 1 BRC repeat plus ssDNA binding domain and NLS are 
sufficient for BRCA2 function 
21
 suggests that the novel BRCA2 proteins in HCC1428 
might be functional. Indeed, HCC1428 cells were resistant to cisplatin (Fig. 1g). 
Furthermore, depletion of these novel BRCA2 proteins with siRNA restored sensitivity of 
HCC1428 cells to cisplatin (Figs. 1f and 1g). 
 HCC1428 was derived after chemotherapy from the pleural effusion of a 49 
year-old woman with stage IV breast carcinoma who died 6 months later 
19
. We speculate 
that the patient’s chemotherapy selected in vivo for secondary mutations in 
BRCA2-mutated breast tumor cells.  
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 To test this hypothesis, we selected in vitro for cisplatin-resistant clones from the 
cisplatin-sensitive BRCA2-mutated pancreatic cancer cell line Capan-1. Capan-1 has the 
mutant allele BRCA2.6174delT, but no wild-type allele (Fig. S5a) 
3, 4
. Fluorescence in situ 
hybridization (FISH) revealed that Capan-1 harbors at least two copies of the BRCA2 
gene indicating duplication of the chromosome 13 with the mutant BRCA2 gene (Fig. 
S2). 
 After selection in cisplatin, we obtained 14 cisplatin-resistant Capan-1 clones 
out of 12 million cells (Fig. S3 and Table S1). Importantly, in 7 of these 14 clones, 
BRCA2 expression, at close to the length of the wild-type protein, was now detectable 
(Fig. 2). The other 7 cisplatin-resistant clones still lacked BRCA2 protein expression. 
 In all 7 cisplatin-resistant clones with restored, nearly full-length BRCA2 
protein expression, we identified additional BRCA2 mutations that corrected the 
frameshift caused by the 6174delT mutation (Figs. 2b, S4, and S5, and Table S1). These 
secondary genetic changes included a small deletion, insertion, and deletion/insertion at 
sites close to the original mutation, and in-frame deletions surrounding the original 
mutation site. Interestingly, in each clone we observed both the original mutant 
BRCA2.6174delT sequence and the 6174delT sequence with additional mutations (Figs. 
S4 and S5) indicating that the secondary mutations occurred on only one of the 
duplicated mutant BRCA2 copies (Fig. S5g). None of the 7 cisplatin-resistant clones 
lacking BRCA2 protein expression harbored additional mutations in BRCA2. 
 Next, we assessed the function of the restored BRCA2 proteins in the 14 
cisplatin-resistant Capan-1 clones by evaluating RAD51 foci formation after exposure to 
ionizing radiation (IR) (Fig. 3a). IR-induced RAD51 foci formation was impaired in 
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parental Capan-1 
1
. In contrast, in 6 of the 7 cisplatin-resistant Capan-1 clones with 
restored BRCA2 expression, IR-induced RAD51 foci formation was significantly 
improved, suggesting that these novel BRCA2 isoforms are functional.  
 In most of the cisplatin-resistant Capan-1 clones without secondary mutations, 
IR-induced RAD51 foci formation remained impaired (Fig. 3a), suggesting that these 
clones acquired cisplatin resistance through mechanisms other than the restoration of the 
BRCA2-RAD51 pathway.  
 Next, we analyzed the homologous recombination (HR)-based DNA 
double-strand-break (DSB) repair function of some of the novel BRCA2 proteins using 
an I-SceI-dependent DR-GFP reporter assay in BRCA2-deficient VC-8 Chinese hamster 
cells 
22
. The proportions of GFP-positive cells arising through the repair of 
I-SceI-induced DSB by HR after transfection of various mutant BRCA2 constructs were 
compared (Figs. 3b and S6, Table S2). Transfection of a wild-type BRCA2 construct 
resulted in about 5-fold more GFP-positive cells compared to transfection of vector 
control or the BRCA2.6174delT mutant. Transfection of constructs with any of the 
secondary BRCA2 mutations resulted in GFP-positive frequencies equal to or greater than 
that of the construct with wild-type BRCA2. These results indicate that the novel BRCA2 
proteins efficiently promote HR.  
 Poly(ADP-ribose) polymerase (PARP) inhibitors selectively kill 
BRCA1/2-deficient tumor cells 
23, 24
 and are expected to become a therapeutic option for 
patients with BRCA1/2-mutated cancers 
13
. However, it remains unclear whether 
BRCA1/2-mutated tumors with acquired cisplatin resistance are sensitive to PARP 
inhibitors. We tested the sensitivity of cisplatin-resistant Capan-1 clones to a PARP 
Sakai, et al.  7 
inhibitor (AG14361) (Fig. 3c). Both parental Capan-1 and cisplatin resistant clones 
without secondary mutations were sensitive to the PARP inhibitor. In contrast, Capan-1 
clones with secondary BRCA2 mutations were resistant, consistent with the restoration of 
functional BRCA2 in these clones, although the differences of the sensitivity between 
parental Capan-1 and these clones were relatively small.  
 Finally, we analyzed tissues of 5 patients with BRCA2 mutations and recurrent 
ovarian carcinomas previously treated with platinum. Three recurrent tumors were 
clinically refractory to platinum and two were sensitive (Table S3). Platinum-refractory 
tumor UW3548 revealed genetic reversion of BRCA2.6174delT (Fig. 4). Evidence for 
genetic reversion is as follows. Constitutional DNA of this patient was heterozygous for 
BRCA2.6174delT and at two single nucleotide polymorphisms (SNPs). As expected, the 
microdissected specimen of the recurrent tumor was hemizygous at each SNP, reflecting 
loss of heterozygosity of BRCA2 in the tumor. However, in the same tumor sample, both 
sequences of BRCA2.6174delT and wild-type BRCA2 were detected, suggesting that the 
recurrent tumor had acquired wild-type BRCA2 by genetic reversion, or back mutation to 
wild-type. We speculate that the appearance of both mutant and wild-type sequences 
resulted from duplication of the mutant BRCA2 followed by genetic reversion of one of 
the duplicates, similar to the situation occurring in Capan-1 clones with secondary 
mutations (Figs. S4 and S5). A larger clinical study is warranted to determine the 
prevalence and clinical significance of in vivo secondary mutations in BRCA2 in human 
tumors. 
 The second platinum-refractory relapsed tumor (CS2) presented a complex 
profile. This patient carried germline mutations in both BRCA1 and BRCA2 (Fig. S7). 
Sakai, et al.  8 
The primary ovarian tumor was sensitive to platinum and showed loss of the wild-type 
BRCA1 allele and heterozygosity of BRCA2, indicating that carcinogenesis was primarily 
driven by the BRCA1 mutation. Importantly, the recurrent platinum-refractory tumor had 
lost the mutant BRCA2 allele. We speculate that loss of the mutant BRCA2 allele was the 
result of selection by chemotherapy and contributed to platinum resistance.  
 The tumor of a third patient (UW174) recurred 5 months after her primary 
chemotherapy, so her tumor is defined as clinically refractory to platinum. No secondary 
mutation in BRCA2 was detectable in the tumor specimen of this patient. Recurrent 
tumors of two other patients (CS9 and CS15) were sensitive to cisplatin. No secondary 
genetic alterations in BRCA2 were identified in either of these tumors.  
 Taken together, our data demonstrate that secondary mutations that correct the 
frameshift caused by mutated BRCA2 alleles are a mechanism of acquired resistance to 
cisplatin (Fig. S8). Testing for secondary mutations in platinum-treated BRCA2-mutated 
cancers may be clinically important, because tumors with secondary mutations are likely 
to be resistant to both cisplatin and PARP inhibitors. Theoretically, it might be possible to 
re-sensitize these tumors to cisplatin and to PARP inhibitors by treatment with drugs such 
as proteasome inhibitors that inhibit RAD51 recruitment to sites of DNA repair 
25
. In 
contrast, platinum-resistant BRCA2-mutated tumors without secondary BRCA2 mutations 
may remain sensitive to PARP inhibitors. 
 Treatment with cisplatin could facilitate secondary mutations by increasing the 
mutation rate via DNA damaging effects. Alternatively, since BRCA2 is involved in 
error-free DNA repair, HR, it is possible that BRCA2 deficiency itself promotes 
secondary mutations through compensatory utilization of more error-prone DNA repair 
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processes 
26
.  
  Secondary mutations are relevant as a mechanism of resistance only in those 
tumors that contain frameshift mutations in BRCA2, which occurs in only 5% of ovarian 
carcinomas. However, BRCA2 mRNA expression is undetectable in 13% of ovarian 
carcinoma 
27
. We speculate that other mechanisms yet to be identified could restore 
BRCA2 in acquired cisplatin resistance in these sporadic cases. 
 Our findings may be applicable to cancers other than ovary. Secondary 
mutations in BRCA2 occurred in a mitomycin C-resistant human acute myeloid leukemia 
cell line with biallelic BRCA2 mutations derived from an FA (D1 subtype) patient 
28
 and 
BRCA2-mutated Chinese hamster fibroblast lines 
29
, suggesting that secondary mutations 
in BRCA2 may have a general role in resistance to DNA-crosslinking agents in cells 
derived from various organs. 
 Secondary mutation of mutated BRCA2 is reminiscent of mechanisms of 
acquired resistance of Philadelphia-chromosome-positive leukemia to imatinib 
30
, such as 
BCR-ABL point mutations that prevent imatinib binding. In both cases, the 
disease-causing mutations increase tumor sensitivity to specific agents, but development 
of further mutations in the disease-causing genes during targeted drug treatment leads to 
drug resistance. It will be important to explore mechanisms for restoring drug sensitivity.  
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METHODS SUMMARY 
 HCC1428, Capan-1, and a lymphoblast cell line (HCC1428BL) were purchased 
from the American Type Culture Collections. Cisplatin-resistant Capan-1 clones were 
generated by long-term culture in cisplatin (2 M)-containing medium. PCR-amplified 
BRCA2 gene fragments were analyzed for sequence alterations with BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems). All nucleotide numbers refer to the 
wild-type cDNA human sequence of BRCA2 (accession no. U43746; version U43746.1 
GI: 1161383) and BRCA1 (U14680.1). 
 For western blot analysis, anti-BRCA2 Ab-1 (1:100; OP95, EMD Biosciences), 
anti-BRCA2 Ab-2 (1:100; PC146, EMD Biosciences), and anti-FANCA (1:1000, (#7488) 
(a gift from Dr. M Hoatlin)) were used. For immunofluorescence microscopy, cells were 
fixed with 4% paraformaldehyde in phosphate buffered saline (PBS) for 10 min, followed 
by permeabilization with 0.25% Triton-X-100 in PBS (10 min). A primary antibody 
(anti-RAD51 (Ab-1) (1:1000, PC130, EMD Biosciences)) and a secondary antibody 
(Alexa Fluor 488 goat anti-rabbit IgG (H+L) antibody (A-11034, Invitrogen)) were used. 
 Cisplatin sensitivity and PARP inhibitor sensitivity of cells were determined 
either by crystal violet or XTT 
(3-1-phenylaminocarbonyl-3,4-tetrazolium-bis(4-methoxy-6-nitrobenzenesulfonic acid) ) 
assays. A PARP inhibitor, AG14631 is a gift of Pfizer. Expression of targeted genes was 
knocked down by transient transfection of siRNA directed against FANCA 
(5'-AAGGGTCAAGAGGGAAAAATA-3'), BRCA2 
(5’-AACAACAATTACGAACCAAAC-3’), and negative control 
(5’-AATTCTCCGAACGTGTCACGT-3’). HR assay was done as previously described 
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22
. A BAC clone, RP11-37E23, was used as a probe for FISH on metaphase chromosome 
preparations of Capan-1 cells. Three DNA samples from BRCA2-mutated ovarian cancer 
patients were obtained from Cedars-Sinai Medical Center (Los Angeles, CA) through the 
Pacific Ovarian Cancer Research Consortium, and two were from the tissue bank of 
University of Washington (Seattle, WA). The study was approved by Institutional 
Review Boards of Fred Hutchinson Cancer Research Center and University of 
Washington.  
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METHODS 
Cell lines. Capan-1, HCC1428BL and breast cancer cell lines (BT-474, BT-483, HCC38, 
HCC1500, HCC1428, HCC1395, MCF7, MDA-MB-231, MDA-MB-436, 
MDA-MB-468) were purchased from American Type Culture Collections (Manassas, 
VA). 21NT was a gift from Dr. K Polyak (Dana Farber Cancer Institute). HCC1937, 
2008 and 2008+FANCF were described 
31, 32
. HCC1428BL were grown in RPMI with 
10% fetal calf serum (FCS) and other cell lines were grown in DMEM with 10% FCS. 
Gamma irradiation was delivered using a linear accelerator. 1.2 x10
7
 Capan-1 cells (10
6
 
cells/15 cm tissue culture plate x 12 plates) were selected in cisplatin (2 M)-containing 
medium. Resistant colonies, appearing after 5–6 weeks, were picked, and expanded in 
normal medium. 
RNA extraction. Total RNAs were extracted using Trizol (Invitrogen; Carlsbad, CA), 
and 2 g of total RNA was placed in 20 L reaction and converted to first-strand cDNA 
using Superscript III RNase H(-) Reverse Transcriptase and oligo(dT)15 (Invitrogen). 
Genomic DNA extraction, PCR and Sequencing of BRCA2 and BRCA1. Genomic 
DNA was extracted from cell lines using QIAamp DNA Blood Mini Kit (Qiagen; 
Valencia, CA). PCR was performed using Expand High Fidelity PCR System (Roche). 
Sequences of PCR products were analyzed with BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems; Foster City, CA). Primers are listed in Tables S4 
and S5. All nucleotide numbers refer to the wild-type cDNA human sequence of BRCA2 
(accession no. U43746; version U43746.1 GI: 1161383) and BRCA1 (U14680.1) 
(GenBank database).  
Western blotting. Cells were lysed with 1x sample buffer (50 mM Tris-HCl pH6.8, 86 
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mM 2-mercaptoethanol, 2% SDS), boiled for 5 min, and subjected to electrophoresis 
using NuPAGE 3-8% Tris-Acetate Gel (Invitrogen). Proteins were transferred to 
nitrocellulose membranes. After blocking with 5% non-fat dried milk in TBS-T (50 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20), the membrane was incubated with the 
primary antibody (BRCA2 Ab-1 (a middle part (a.a. 1651-1821) of BRCA2) (1:100; 
OP95, EMD Biosciences; San Diego, CA), BRCA2 Ab-2 (C-terminus (a.a.3245–3418) of 
BRCA2) (1:100; PC146, EMD Biosciences), FANCA (1:1000, #7488, gift from Dr. M 
Hoatlin, Oregon Health and Science University) diluted in TBS-T, and incubated with the 
appropriate horseradish peroxidase-linked secondary antibody (Amersham). 
Chemiluminescence was used for detection.  
Immunofluorescence microscopy. Cells were fixed with 4% paraformaldehyde in PBS 
for 10 min and permeabilized with 0.25% Triton-X-100 in PBS. After blocking in 
blocking buffer (3% bovine serum albumin/0.05% Triton X-100/0.04% sodium 
azide/PBS), a primary antibody (RAD51 (1:1000, PC130, EMD Biosciences)) diluted in 
blocking buffer was added and incubated for 1-2 hours. A secondary antibody (Alexa 
Fluor 488 goat anti-rabbit IgG (H+L) antibody (A-11034, Invitrogen)) (1:1000) was 
added and incubated for 1 hour. The nuclei were counterstained with 4’, 
6-diamidino-2-phenylindole dihydrochloride. Images were captured on a microscope 
(TE2000, Nikon, Tokyo) through a CCD camera and processed using MetaVue 
(Universal Imaging, Downington, PA) and Photoshop (Adobe). Cells with five or more 
RAD51 foci were scored as positive. At least 100 cells per experimental point were 
scored.  
Cytotoxicity assays. Drug sensitivity was determined by crystal violet or XTT 
Sakai, et al.  14 
(3-1-phenylaminocarbonyl-3,4-tetrazolium-bis(4-methoxy-6-nitrobenzenesulfonic acid) ) 
assays as previously described 
33-35
. Cells were seeded onto 12-well plates at 6 x 10
3
 
cells/well in DMEM-10% FCS (1.5 ml). After cells attached, the medium was replaced 
with DMEM-10% FCS containing cisplatin or a PARP inhibitor, AG14631 (a gift of 
Pfizer, La Jolla, CA) 
36
, at various concentrations. After incubation for 10 days, 
monolayers were fixed for 5 to 10 min in 10% methanol and 10% acetic acid. Adherent 
cells were stained with 1% crystal violet in methanol (0.5 ml/well). The adsorbed dye 
was resolubilized with methanol containing 0.1% SDS (0.3 ml/well). Dye solution (200 
l) was transferred to 96-well plates and diluted (1:2) in methanol. Crystal violet 
concentrations were measured photometrically (595 nm) in a microplate reader. For XTT 
assays, cells were seeded in 96-well plates at 2 x 10
3
 cells/well (for HCC1428 and 
Capan-1 in Figure 1g) or 8 x 10
2
 cells/well (for Capan-1 and its clones in Figure 3c), and 
cisplatin or AG14631 was added at varying concentrations. After 5 or 6 days, the number 
of viable cells was measured by the XTT assay as previously described 
37
. For HCC1428 
cells, we only used XTT assays, because HCC1428 do not grow in the condition for the 
crystal violet assays. 
siRNA transfection. HCC1428 cells (3x10
5
 cells) were plated in 6-well plates at the time 
of transfection in 2 ml of complete media. siRNA oligos (FANCA 
(5'-AAGGGTCAAGAGGGAAAAATA-3') 
38
, BRCA2 
(5’-AACAACAATTACGAACCAAAC-3’) 
38
, and negative control 
(5’-AATTCTCCGAACGTGTCACGT-3’)) were diluted in 400 L DMEM and were 
mixed with 12 L of HiPerFect reagent (Qiagen). Complex formation was allowed to 
proceed for 10 min at room temperature prior to addition to cells. Final concentration of 
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siRNA was 50 nM. Two days after transfection, cells were seeded in 96-well plates for 
cisplatin sensitivity assay.  
Homologous recombination (HR) assay. Nucleotide changes were incorporated into 
BRCA2 cDNA pcDNA3.1 subclones using the QuikChange kit (Stratagene; La Jolla, 
CA). Mutant partial cDNA fragments were subcloned into a FLAG-tagged full-length 
BRCA2 cDNA pcDNA3.1 plasmid. VC8-DR-GFP cells 
22
 were transfected with either 
pcDNA3.1 vector, pcBAsce1 vector containing the I-SceI restriction endonuclease gene, 
or pcBAsce1 plus various FLAG tagged BRCA2-pcDNA3.1 constructs. The percentage 
of GFP positive cells was quantitated by flow cytometric analysis 72 hours after 
transfection as described 
22
. In parallel, the percentage of VC8-DR-GFP cells expressing 
the various constructs were determined by immunofluorescence with anti-FLAG 
antibody and were used to normalize the HR data for VC8 transfection efficiency. 
Fluorescence In Situ Hybridization (FISH). A BAC clone, RP11-37E23, was used as a 
probe for FISH on metaphase chromosome preparations of Capan-1 cells using 
procedures detailed previously 
39
. 
Clinical specimens. Three DNA samples from BRCA2-mutated ovarian cancer patients 
were obtained from Cedars-Sinai Medical Center through the Pacific Ovarian Cancer 
Research Consortium, and two DNA samples were from the tissue bank of University of 
Washington. DNA from UW3548 was obtained after laser capture microdissection. The 
study was approved by Institutional Review Boards of Fred Hutchinson Cancer Research 
Center and University of Washington.  
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Figure Legends 
 
Figure 1. HCC1428 is a cisplatin-resistant breast cancer cell line with a secondary 
BRCA2 mutation. (Full-length blots are presented in Supplemental Figure 9) 
a, Cell lysates from HeLa, Capan-1 and indicated breast cancer cell lines were 
immunoblotted with BRCA2 antibodies.  b, Genomic DNA sequence of BRCA2 in 
HCC1428BL lymphoblast. A heterozygous mutation (6174delT) was identified.  c, 
Genomic DNA sequence of BRCA2 in HCC1428 breast cancer cell line. A homozygous 
2135-base deletion from nt5140 (in exon 11) to IVS11+205 (in intron 11) was identified.  
d, Sequences of the two BRCA2 transcripts in HCC1428 breast cancer cell line. The two 
RT-PCR products shown in Fig. S1b were purified from the gel, and sequenced 
separately. HCC1428 transcripts 1 and 2 had a 2640-base deletion (nt4430 to 7069) and a 
2187-base deletion (nt4883 to 7069), respectively, suggesting activation of the cryptic 
splice donor sites in exon11. e, Schematic presentation of BRCA2 proteins. The regions 
that the BRCA2 antibodies (Ab-1 and Ab-2) recognize are also depicted. HCC1428 
transcripts 1 and 2 encode BRCA2 lacking 881 amino acids and 730 amino acids, 
respectively, both of which have ssDNA binding domains, nuclear localization signals 
(NLS) and some of the BRC repeats.  f, Cell lysates from HCC1428 cells treated with 
indicated siRNA were immunoblotted with BRCA2 and FANCA antibodies. 2008 and 
2008+FANCF were used as controls.  g, Cisplatin sensitivity assessed by XTT assay. 
HCC1428 was resistant to cisplatin, and depletion of BRCA2 or FANCA sensitized 
HCC1428 to cisplatin (mean ± SEM, n=3).  
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Figure 2. Secondary genetic changes in mutated BRCA2 in cisplatin-resistant clones 
of a pancreatic cancer cell line, Capan-1. (Full-length blots are presented in 
Supplemental Figure 9) a, Seven Capan-1 clones indicated with a single asterisk (*) 
restored apparently full-length BRCA2 protein expression. Cell lysates from indicated 
cells were immunoblotted with BRCA2 antibodies (Ab-1 and Ab-2). A double asterisk 
(**) indicates a band presumed to be nonspecific. b, Schematic presentation of BRCA2 
proteins encoded by transcripts in Capan-1 clones. In all of the BRCA2-restored Capan-1 
clones, additional genetic changes in exon 11 of BRCA2 were detected (Table S1, Figs. 
S4 and S5). All of these secondary genetic changes (shown as white arrow heads or black 
horizontal bars) cancel the frameshift caused by the original mutation (6174delT, black 
arrow heads), and the encoded BRCA2 proteins have intact C-terminal regions containing 
a single strand DNA (ssDNA) binding domain and nuclear localization signals (NLS).  
 
Figure 3. Functional analyses of the restored BRCA2 proteins. a, Ionizing radiation 
(IR)-induced RAD51 foci formation is restored in most of BRCA2-restored Capan-1 
clones. Indicated cells were irradiated (15 Gy) and fixed 12 hours after IR. Cells were 
immunostained with RAD51 antibody. Representative pictures of immunostained cells 
after IR are shown, together with quantification of the cells with at least five RAD51 foci 
before (-, white bars) and 12 hours after IR (+, grey bars) (mean values of at least three 
independent experiments ± SEM). Asterisks (*) indicate significant difference with 
irradiated parental Capan-1 cells (p<0.05, unpaired t test). Scale bar = 40 μm. b, 
Quantitation of HR induced by I-SceI in VC8-DR-GFP cells transiently transfected with 
wild-type and mutant forms of FLAG-tagged human BRCA2 cDNA. The proportion of 
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GFP-positive cells for each construct relative to vector control is shown (mean ± SEM, 
n=3). c, BRCA2-restored Capan-1 clones are resistant to a PARP inhibitor. Capan-1, its 
clones with secondary BRCA2 mutation (C2-6, C2-12 and C2-14) and clones without 
secondary BRCA2 mutation (C2-10, C2-11 and C2-13) were treated with a PARP 
inhibitor (AG14361) at the indicated concentrations for 6 days, and survival fraction was 
measured by XTT assay (mean ± SEM, n=6).  
 
Figure 4. Genetic reversion of BRCA2 in platinum-resistant recurrent 
BRCA2-mutated ovarian cancer. DNA sequences of BRCA2 in peripheral blood 
lymphocytes and a microdissected specimen of the recurrent tumor from a patient 
(UW3548) with BRCA2-mutated ovarian cancer previously treated with cisplatin. In the 
lymphocytes, heterozygous single nucleotide polymorphisms (SNPs) of the BRCA2 locus 
(IVS21-66C/T and IVS25-299C/G) were detected, in addition to a heterozygous mutation 
(6174delT). In the microdissected recurrent tumor specimen, loss of heterozygosity 
(LOH) of the SNPs was confirmed, but mixed sequences of 6174delT and wild-type 
BRCA2 were detected.  
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1. Supplemental Figures. 
 
Figure S1. BRCA2 of HCC1428BL lymphoblast line and HCC1428 breast cancer 
cell line.  a, Ethidium bromide-stained agarose gel electrophoresis of the genomic PCR 
products from HCC1428 and HCC1428BL. The primers, B2F3785 and B2R6932, were 
used for the amplification. The molecular weight size standard is a 1000-bp ladder. A 
smaller PCR product was detected in HCC1428. b, Ethidium bromide-stained agarose gel 
electrophoresis of the RT-PCR products from HCC1428 and HCC1428BL. The primers, 
B2F3785 and B2R8452, were used for the amplification. The molecular weight size 
standard is a 1000-bp ladder. Two smaller RT-PCR products (transcripts 1 and 2) were 
detected in HCC1428. c, Schematic presentation of BRCA2 alleles. HCC1428BL had 
wild-type and mutant (6174delT) alleles. HCC1428 lost the wild-type allele and retained 
the mutant allele with an additional internal deletion. The HCC1428’s mutant allele had a 
2135-bp deletion, which activates two cryptic splice donor sites in exon 11, resulting in 
the expression of transcripts 1 and 2. 
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Figure S2. Multiple copies of BRCA2 gene in Capan-1.  Representative pictures of 
BRCA2 FISH on metaphase chromosomes of Capan-1 cells.  a, This cell has a short 
chromosome 13 (yellow arrow) and a normal-looking chromosome 13 (white arrow), 
both of which have one BRCA2 signal (red). Therefore, the cell has at least 2 copies of 
BRCA2 gene. b, This cell has a normal-looking chromosome 13 (white arrow) with one 
BRCA2 signal (red) and an isochromosome 13 (green arrow) with two BRCA2 signals 
(red). Therefore, the cell has at least 3 copies of BRCA2 gene. An interphase nucleus 
(white arrow head) also shows three BRCA2 signals (red). 
 
 
 
 
 
 
 
 
 
Supplementary-Sakai 4 
 
 
 
 
 
 
 
Figure S3. Cisplatin-selected clones of a pancreatic cancer cell line, Capan-1. Fifteen 
subclones of Capan-1 were generated by selecting the cells in the presence of cisplatin. 
Fourteen clones (except C2-3) were resistant to cisplatin compared to the parental 
Capan-1 cells. The cells were treated with cisplatin at the indicated concentrations for 10 
days, and survival fraction was measured by crystal violet assay. Mean values of at least 
three independent experiments ± SEM are shown. 
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Figure S4. BRCA2 sequences of transcripts in Capan-1 clones.  a, Ethidium 
bromide-stained agarose gel electrophoresis of the RT-PCR products from Capan-1 and 
its clones. The primers, B2F5391 and B2R6932, were used for the amplification. The 
molecular weight size standard is a 1000-bp ladder. Asterisk (*) indicates clones with 
restored BRCA2 protein expression. In C2-5 and C2-6, smaller RT-PCR products, in 
addition to normal size products, were detected.  b, Sequence of BRCA2 transcript in 
parental Capan-1 cells. A BRCA2 mutation (6174delT) was detected.  c, BRCA2 
sequence in clone C2-1. Mixed sequences of the original sequence (6174delT) and the 
sequence with an additional mutation (6174delT; 6232_6238del7ins14) were detected. 
C2-2 showed the same pattern (data not shown). d, C2-4. Mixed sequences of the original 
sequence (6174delT) and the sequence with an additional mutation (6174delT; 
6191_6192insT) were detected. C2-14 showed the same pattern (data not shown).  e, 
C2-5. Mixed sequences of the original sequence (6174delT) and the sequence with an 
additional mutation (6006_6308del303) were detected. The signals derived from the 
original sequence were much weaker than those from 6006_6308del303 sequence, 
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consistent with the ratio of intensities of 1.6kb (the original sequence, weak) and 1.3kb 
(6006_6308del303, strong) bands in lane 6 of Fig S4A.  f, C2-6. The two RT-PCR 
products shown in Fig. S4A lane 7 were purified from the gel, and sequenced separately. 
In the smaller RT-PCR product (1.1kb), the sequence with an additional mutation 
(5870_6365del496ins4)) was detected. In the normal size product (1.6kb), the original 
sequence (6174delT) was detected (data not shown).  g, C2-12. Mixed sequences of the 
original sequence (6174delT) and the sequence with an additional mutation (6174delT; 
6186_6226del41) were detected. All of these mutations were confirmed in genomic DNA 
as shown in Fig S5. 
 
  
Figure S5.  BRCA2 sequences of genomic DNAs from Capan-1 clones. 
a, Parental Capan-1 cells. A BRCA2 mutation (6174delT) was detected.  b, C2-1. Mixed 
sequences of the original sequence (6174delT) and the sequence with an additional 
mutation (6174delT; 6232_6238del7ins14) were detected. C2-2 showed the same pattern 
(data not shown).  c, C2-4. Mixed sequences of the original sequence (6174delT) and 
the sequence with an additional mutation (6174delT; 6191_6192insT) were detected. 
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C2-14 showed the same pattern (data not shown).  d, C2-5. Mixed sequences of the 
original sequence (6174delT) and the sequence with an additional mutation 
(6006_6308del303) were detected.  e, C2-6. Mixed sequences of the original sequence 
(6174delT) and the sequence with an additional mutation (5870_6365del496ins4) were 
detected.  f, C2-12. Mixed sequences of the original sequence (6174delT) and the 
sequence with an additional mutation (6174delT; 6186_6226del41) were detected.  g, 
Schematic model of the secondary mutations in Capan-1 clones. Capan-1 has lost a 
wild-type BRCA2 allele, but has retained an allele with the inherited mutation 
(6174delT). This mutant allele has been duplicated (or triplicated), according to the FISH 
data shown in Fig. S2. In Capan-1 clones with secondary mutations, the secondary 
genetic change occurs only on one of the mutant BRCA2 copies. This model explains 
why we see mixed sequences of BRCA2 in all of the Capan-1 clones with secondary 
BRCA2 mutations. 
 
 
Figure S6.  Expression of FLAG-BRCA2 mutant proteins used for the DR-GFP 
homologous recombination assay. FLAG-tagged BRCA2 variants used for the DR-GFP 
homologous recombination assay shown in Fig 3b were transiently expressed in 293T 
cells, immunoprecipitated with anti-FLAG (M2) (Sigma), and analyzed by Western 
blotting using a BRCA2 antibody (Ab-1, EMD Biosciences). 
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Figure S7.  DNA sequences of BRCA1 and BRCA2 in peripheral blood 
lymphocytes, and pre-treatment and recurrent tumors from a patient (CS2) with 
BRCA1-BRCA2-doubly mutated ovarian cancer.  The lymphocytes showed 
heterozygous mutations of both BRCA1 (1912T>A) and BRCA2 (8765_8766delAG). 
Before treatment, the primary tumor showed LOH of BRCA1 (loss of wild-type BRCA1), 
and hetrozygosity of BRCA2. The post-treatment recurrent tumor showed LOH of BRCA1 
(loss of wild-type BRCA1) and LOH of BRCA2 (loss of mutant BRCA2).  
 
  
Figure S8. Schematic model for involvement of a secondary BRCA2 mutation in 
development of resistance to cisplatin in a BRCA2-mutated tumor. See text for detail.  
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Figure S9. Non-cropped pictures of blots. 
(a, b, c) Non-cropped pictures of blots presented in Figure 1a. 
(d, e, f) Non-cropped pictures of blots presented in Figure 1f. 
(g, h, i, j) Non-cropped pictures of blots presented in Figure 2a. 
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2. Supplemental Tables 
 
Table S1. Summary of characterization of cisplatin-selected Capan-1 clones. BRCA2 
sequence, BRCA2 protein expression, and cisplatin sensitivity of Capan-1 and its clones 
are summarized.  
 
Table S1. Characterization of cisplatin-selected Capan-1 clones.     
        
          BRCA2 Cisplatin sensitivity 
Name of originated BRCA2 mutation   protein  IC50 (mean±SEM) 
clone from inherited additional  Type of secondary mutation expression   (uM) 
C2-1 plate #1 6174delT 6232_6238del7ins14 second site deletion and insertion + R 2.09±0.15 
C2-2 plate #1 6174delT 6232_6238del7ins14 second site deletion and insertion + R 2.49±0.39 
C2-3 plate #2 6174delT not found N/A - S 0.34±0.08 
C2-4 plate #3 6174delT 6191_6192insT second site insertion + R 0.73±0.16 
C2-5 plate #3 6174delT 6006_6308del303 in-frame deletion surrounding nt6174 + R 0.72±0.08 
C2-6 plate #3 6174delT 5870_6365del496ins4 in-frame deletion surrounding nt6174 + R 0.86±0.15 
C2-8 plate #4 6174delT not found N/A - R 0.75±0.12 
C2-10 plate #5 6174delT not found N/A - R 1.16±0.06 
C2-11 plate #6 6174delT not found N/A - R 0.69±0.05 
C2-12 plate #7 6174delT 6186_6226del41 second site deletion + R 0.71±0.08 
C2-13 plate #8 6174delT not found N/A - R 1.07±0.28 
C2-14 plate #9 6174delT 6191_6192insT second site insertion + R 1.48±0.10 
C2-15 plate #10 6174delT not found N/A - R 0.74±0.07 
C2-16 plate #11 6174delT not found N/A - R 0.73±0.18 
C2-18 plate #12 6174delT not found N/A - R 0.71±0.07 
Capan-1 N/A 6174delT N/A N/A - S 0.46±0.03 
        
    
abbreviations: N/A; not applicable, 
ND; not done, R; resistant, S; 
sensitive    
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Table S2. Evaluation of homology-directed repair of the FLAG-BRCA2 mutants.  
 Vector Wild-type 6174delT 
C2-4, 
C2-14 
C2-5 C2-12 
Mean GFP positive cells  
± SEM 
214 
± 8 
1073 
± 69 
316 
± 9 
1114 
± 39 
1771 
± 25 
1540 
± 27 
Relative transfection 
efficiency (compared to 
wild-type BRCA2 construct) 
determined by 
immunofluorescence with 
anti-FLAG antibody 
~ 1.0 1.1 0.7 0.9 1.3 
Normalized  
GFP positive cells 
~ 1073 297 1620 2024 1173 
Fold induction 
relative to vector 
± SEM 
1.0 
± 0.1 
5.0 
± 0.3 
1.4 
± 0.1 
7.6 
± 0.3 
9.5 
± 0.1 
5.5 
± 0.1 
Raw data of Figure 3b.  
 
Table S3. Summary of genetic changes in clinical specimens of recurrent 
BRCA2-mutated ovarian cancer treated with platinum.  
Table S3.  Summary of genetic changes in clinical specimens of recurrent BRCA2-mutated ovarian cancer treated with platinum 
    Clinical platium response       Secondary 
Patient  specimen at the time of sampling 
Mutated 
gene Inherited mutation LOH genetic change 
 Paired specimens     
       
CS9 pre-platinum sensitive BRCA2 6174delT Yes (loss of WT) No 
 post-platinum sensitive BRCA2 6174delT Yes (loss of WT) No 
       
CS15 pre-platinum sensitive BRCA2 2699delT Yes (loss of WT) No 
 post-platinum sensitive BRCA2 2699delT Yes (loss of WT) No 
       
CS2 pre-platinum sensitive BRCA1 1912T>A (L598X) Yes(loss of WT) No 
   BRCA2 8765_8766delAG No No 
 post-platinum refractory  BRCA1 1912T>A (L598X) Yes (loss of WT) No 
   BRCA2 8765_8766delAG Yes (loss of mt) Yes (loss of mt) 
       
 Non-paired post-treatment specimens     
       
UW174 post-platinum refractory BRCA2 5578_5579delAA Yes (loss of WT) No 
       
UW3548 post-platinum refractory BRCA2 6174delT Yes (LOH of SNPs)  
          
gain of wild-type 
sequence Yes (back mutation) 
       
 abbreviations: LOH; loss of heterozygosity, mt: mutant allele, SNP; single nucleotide polymorphism, WT; wild-type allele 
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Table S4. Primers used for BRCA2 sequencing and PCR. 
# Primer Seq 5' to 3' 
1 B2Pro1F TCCGAATCCTAAGAATGCAAA 
2 B2Pro1R GCGAGGGCTTGGTAGTATCT 
3 B2Pro2F CACCCAGGCCTGACTTCC 
4 B2Pro2R CACGCTGGACTGGGACTG 
5 B2Pro3F GGTAGTGGGTTGGGACGAG 
6 B2Pro3R ATGGCGTCATCTGGGACA 
7 B2Pro4F CTAGCCACGCGTCACTGGT 
8 B2Pro4R TCTGCAAAACAGAAGACCAAAA 
9 B2Pro5F ACTGGCCCCTTGACTAGCAG 
10 B2Pro5R GCCAGGCTGGTCTCAAACT 
11 B2F-125 TCTGAAACTAGGCGGCAGAG 
12 B2R32 AATGTTGGCCTCTCTTTGGA 
13 B2F420 TGAAAGTCCTGTTGTTCTAC 
14 B2R586 TTGACCAAGACATATCAGGA 
15 B2F806 CATCAGGGAATTCATTTAAAGT 
16 B2R848 ATGTGGTCTTTGCAGCTATTTA 
17 B2F1178 GAATGGTCTCAACTAACCCT 
18 B2F1561 TCAGGTCATATGACTGATCC 
19 B2F1934 GAAGCTGTTCACAGAATGAT 
20 B2R2208 TGCAGCCAAGACCTCTTCTT 
21 B2F2314 ACTCCTACTTCCAAGGATGT 
22 B2R2365 GCAGGCATGACAGAGAATCA 
23 B2F2689 GAAAGGAATAATCTTGCTTTAG 
24 B2F3016 GGAGGTAGCTTCAGAACAGC 
25 B2F3173 AACTGAGCAAGCCTCAGTCAA 
26 B2F3398 CAAGCTACATATTGCAGAAG 
27 B2R3548 TCAAATTGCTTGCTGCTGTC 
28 B2F3785 CAAGTAAATGTCATGATTCTGTTG 
29 B2F4190 AAGCATGTCATGGTAATACTTC 
30 B2R4382 GGAAAAGTTATGCAATTCTTCTGG 
31 B2R4528 GTTGTCCCTGGAAGGTCACT 
32 B2F4600 ATTGCAAAGGAATCTTTGGA 
33 B2R4840 TAGGTGGCACCACAGTCTCA 
34 B2F4985 CAGTCATTGAAAATTCAGCCTTAG 
35 B2R5202 TTCGGAGAGATGATTTTTGTCAT 
36 B2F5391 AAATGCATACCCACAAACTG 
37 B2R5534 CTAAATGCAGGTGGCCCTAC 
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38 B2F5741 GCACGCATTCACATAAGGTTT 
39 B2F5796 TAACCAAAATATGTCTGGATTGGAG 
40 B2R5859 TTCCAAACTAACATCACAAGGTG 
41 B2F5836 TCACCTTGTGATGTTAGTTTGGA 
42 B2F5925 TGGGATTTTTAGCACAGCAA 
43 B2R5928 CCCACAAGTATTTGCAGATGAG 
44 B2R5990 CTTGCGTTTTGTAATGAAGCA 
45 B2R6076 TGAGCTGGTCTGAATGTTCG 
46 B2F6193 CAAGTTTCCATTTTAGAAAGTTCCT 
47 B2R6202 TGGAAACTTGCTTTCCACTTG 
48 B2F6592 GAAACTTTTTCTGATGTTCCTGTGA 
49 B2R6496 CCAACTGTTGTTTGTCTTGTTGA 
50 B2R6692 GCAATTTCTACTGCTTCTGTTTCA 
51 B2R6932 GGAGTGCTTTTTGAAGCCTTT 
52 B2F7000 CCCTTTCGCACAACTAAGGA 
53 B2F7402 GTAACTTTCACAAAGTGTGAAGA 
54 B2F7810 CTGTGTGACACTCCAGGTGT 
55 B2R8452 CACAACCAACATTTCCTCCA 
56 B2F8565 GGAGGCCCAACAAAAGAGAC 
57 B2R8923 CAATACGCAACTTCCACACG 
58 B2F8960 TGAGTATTTGGCGTCCATCA 
59 B2F9362 CTGCAAGCAACCTCCAGTG 
60 B2F9905 GGAGTTGTGGCACCAAATACGAAAC 
61 B2F10259 CATTTGCAAAGGCGACAATA 
62 B2R10303 CTGGAAAGGTTAAGCGTCAA 
63 B2F10396 GTGTATCGGGCAAAAATCGT 
64 B2F10663 TCTTTGGATTTGATCACTACAAGT 
65 B2R10797 GCTAAACTAAAAGGAATTATCTGCATC 
66 B2F10933 CAATTCTTCATCCTTAAGTCAGCA 
67 B2F11129 TTGCTTTCAAATTGGCACTG 
68 B2R11158 CAGTGCCAATTTGAAAGCAA 
69 B2F.IVS10-237 TACACCACCACACCCAGCTA 
70 B2F.IVS12-221 TGCTGATTTCTGTTGTATGCTTG 
71 B2R.IVS13+278 TGATTCGGAGCAATTTCCTT 
72 B2F.IVS16-59 TTGAATTCAGTATCATCCTATGTGG 
73 B2R.IVS17+135 GAGAACAGCAGTGTGGGATG 
74 B2F.IVS18+1419 CTCAGAGGCTTGTTGGGAAA 
75 B2R.IVS18+1769 AGGCCAGGTACAGTGGTTCA 
76 B2F.IVS18+2497 TGCCATGTTTTATAGATTTGTCTTT 
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77 B2R.IVS18+2914 TCACATCTGCACCTTTCTCTG 
78 B2F.IVS19-174 GGGGTTTCATCATGTTGGTC 
79 B2R.IVS20+179 TGTCCCTTGTTGCTATTCTTTG 
80 B2F.IVS20-1695 GGGAGGCCTCAGGAAACTTA 
81 B2R.IVS20-1271 TGATTCCAACCCTCATGGAT 
82 B2R.IVS21-206 GGAGGATCATTTTTGCCGTA 
83 B2F.IVS24+127 GCCTCTTTGAACCTCTGATTTT 
84 B2R.IVS24+551 CGGTGGCGGGTATATGTAGT 
85 B2F.IVS25-492 CCAGTTGTGATTTCTCAAGCA 
86 B2R.IVS25-76 AAAGCAGAAATGAAAAGTTTGGA 
 
 
Table S5. Primers used for BRCA1 sequencing and PCR. 
# Primer Seq 5' to 3' 
1 B1F3 CTCGCTGAGACTTCCTGGAC 
2 B1R418 TCCAAACCTGTGTCAAGCTG 
3 B1F878 AGCTGAGAGGCATCCAGAAA 
4 B1R972 GCTGTAATGAGCTGGCATGA 
5 B1F1311 TCACATGATGGGGAGTCTGA 
6 B1F1641 CCTACATCAGGCCTTCATCC 
7 B1R2114 GTTTCTGCTGTGCCTGACTG 
8 B1F2095 CAGTCAGGCACAGCAGAAAC 
9 B1F2280 TTTGTCAATCCTAGCCTTCCA 
10 B1F2494 GGAAGGCAAAAACAGAACCA 
11 B1R2504 TTTTGCCTTCCCTAGAGTGC 
12 B1F2717 CCAGTCATTTGCTCCGTTTT 
13 B1R2743 GGATTTGAAAACGGAGCAAA 
14 B1R2921 CTGACCAACCACAGGAAAGC 
15 B1F2997 GGCAACGAAACTGGACTCAT 
16 B1R3247 TTGCTTGAGCTGGCTTCTTT 
17 B1R3361 TTCAATTTTGGCCCTCTGTT 
18 B1F3524 GCCTATGGGAAGTAGTCATGC 
19 B1F3653 CAAAAGCGTCCAGAAAGGAG 
20 B1R3876 ACAGACACTCGGTAGCAACG 
21 B1F4100 GTCTGAAAGCCAGGGAGTTG 
22 B1F4305 CAGAGGGATACCATGCAACA 
23 B1F4530 GGCCTTTCTGCTGACAAGTT 
24 B1F5120 GTTTGCCAGAAAACACCACA 
25 B1R5668 AGCTCCTGGCACTGGTAGAG 
Supplementary-Sakai 15 
26 B1F101-378 ATTGGTGTTGGTTTGGTCGT 
27 B1F101-159 TCTTTAAAAATAAAGGACGTTGTCA 
28 B1R199+143 TTCAGTTAAGAAAATCAGCAATTACA 
29 B1R199+451 TCTCGATCTCCTGACCTCGT 
30 B1F200-352 GATGAGATGTGCACCCACAG 
31 B1F200-206 GCTCACTGAAGGTAAGGATCG 
32 B1R253+190 TTACCAGGAACTATGATTACAACCAA 
33 B1R253+451 AGGTGGATCACAAGGTCAGG 
34 B1F.IVS10-294 CTGATGGCCAATCTGCTTTT 
35 B1R.IVS11+33 ACTGGGGCAAACACAAAAAC 
36 B1F.IVS15-47 TTCAACATTCATCGTTGTGTAAA 
37 B1R.IVS16+1 CAAATTCTTCTGGGGTCAGG 
 
